Search Results

Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET.

Talphera, Inc. announced that the Board of Directors of Talphera has granted inducement awards consisting of a non-statutory time-based stock option to purchase 185,000 shares of common stock and a time-based restricted stock unit award for 32,000 shares of common stock on May 20, 2024 to Dr. Shakil Aslam in connection with his appointment as the Chief Development Officer of Talphera in May 2024.

Talphera, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced first quarter 2024 financial results and provided a corporate update.

Talphera, Inc. (Nasdaq: TLPH), (“Talphera”) today announced that it will release first quarter 2024 financial results after market close on Tuesday, May 14, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company’s business.

AcelRx Pharmaceuticals, Inc. today announced the rebranding of the Company, with a name change to Talphera, Inc. (“Talphera”).

Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter 2023 financial results and provided a corporate update.

Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2023 financial results after market close on Wednesday, March 6, 2024.

Talphera, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced as part of its commitment to operating with best practices in corporate governance, its Board of Directors has decided to reduce the size of the Board from ten to seven directors.